Production of human elafin by genetically modified Lactococcus lactis: evaluation of its anti-inflammatory effects in a murine model of intestinal mucositis

What is it about?

Considering that mucositis affects many patients undergoing chemotherapy, the aim of this study was to study an alternative to reduce inflammation at the intestinal level. To do this, we studied a recombinant bacteria designed to produce an anti-inflammatory molecule called elafin. The impact of this recombinant strain was analyzed in cell cultures and in animal models. The in vitro results showed that the elafin-producing strain improved the toxicity of the drug used in chemotherapy (5-Fluorouracil), protecting non-tumor cells. In the animal model, the strain reduced the appearance of diarrhea, improved intestinal absorption, and decreased inflammation.

Featured Image